|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-01-0003.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Molecular Genetics, Graduate
School of Medicine, Kyoto University, Japan; Department of Genetics,
Institute of Medical Science, University of Tokyo, Japan;
and Riken Center for Developmental Biology, Kobe, Japan.
Vascular endothelial growth factor (VEGF) is a major growth factor
for developing endothelial cells (ECs). Embryonic lethality due to
haploinsufficiency of VEGF in the mouse highlighted the strict dose
dependency of VEGF on embryonic vascular development. Here we
investigated the dose-dependent effects of VEGF on the differentiation
of ES cell-derived fetal liver kinase 1 (Flk-1)/VEGF receptor
2+ (VEGFR2+) mesodermal cells into ECs
on type IV collagen under a chemically defined serum-free condition.
These cells could grow even in the absence of VEGF, but differentiated
mostly into mural cells positive for Vascular endothelial growth factor (VEGF), also
known as vascular permeability factor,1-3 has been
implicated as the major growth factor for developing endothelial cells
(ECs). Targeted disruption of the VEGF gene in mice did not
only show the important role for VEGF in embryonic vascular
development, but also presented embryonic lethality due to
haploinsufficiency of VEGF.4,5 Carmeliet et
al4 indeed emphasized that VEGF deficiency
constituted the most severe haploid-insufficient phenotype reported to
date. Moreover, deletion of a single VEGF allele in
collagen2a1-Cre-expressing cells was reported to result in embryonic
lethality around E10.5.6 These studies highlighted the
strict dose-dependent effects of VEGF on embryonic vascular development.
Fetal liver kinase 1 (Flk-1)/VEGF receptor 27 (VEGFR2) is
one of the receptors of VEGF.8 The role for VEGFR2 in the
development of ECs and hematopoietic cells (HCs) has been intensively
studied as VEGFR2 is a receptor tyrosine kinase expressed by a subset of mesodermal cells9,10 and gene-targeting studies showed that VEGFR2 was essential for the development of ECs and HCs during embryogenesis.11,12 Consistent with the in vivo studies,
we and another group previously reported that VEGFR2+
mesodermal cells derived from mouse embryonic stem (ES) cells or
isolated from the early chicken gastrula could differentiate into ECs
and HCs in vitro.13,14 The blast colony-forming cells expressing VEGFR2 derived from ES cells were reported to give rise to
both lineages.15 In addition, we demonstrated that
VEGFR2+ cells derived from ES cells could differentiate
into mural cells such as pericytes and vascular smooth muscle
cells.16
Fms-like tyrosine kinase (Flt-1)/VEGFR117 is another
receptor of VEGF.18 The expression of VEGFR1 is first
turned on in the extraembryonic mesoderm and is eventually confined to
ECs.19,20 Targeted disruption of VEGFR1 gene in
mice resulted in embryonic lethality with overpopulation of ECs, and
chimeric analysis using VEGFR1 null mutant ES cells showed that the EC
development was affected in a cell nonautonomous
manner.21,22 Moreover, VEGFR1 lacking the tyrosine kinase
domain is sufficient for normal vascular development in
mice.23 These studies indicated that a major function of
VEGFR1 during embryogenesis is to regulate VEGFR2 signal negatively by
sequestering VEGF rather than to transduce VEGFR1 signal itself. This
was also suggested by the biochemical analysis showing that the
affinity of VEGFR1 to VEGF is at least 10-fold higher than that of
VEGFR2, but its tyrosine kinase activity is 10-fold weaker than that of
VEGFR2.24
To investigate the dose-dependent effects of VEGF on EC development,
the in vitro cellular events of VEGFR2+ mesodermal cells
from ES cells or from chicken embryos were analyzed in the presence of
various doses of VEGF.14,25 By using a feeder cell-dependent culture system, we have demonstrated the dose-dependent effects of VEGF on cellular events of VEGFR2+ mesodermal
cells. However, because VEGF did not support the growth of
VEGFR2+ mesodermal cells on a certain feeder cell layer,
the cellular events on the feeder cell layer were induced by VEGF in
combination with undefined molecules derived from animal sera and
feeder cells.25 Establishment of a culture system in a
defined culture medium without feeder cells has been awaited to further
address the issue on the response of VEGFR2+ mesodermal
cell to VEGF.
Here we report that ES cell-derived VEGFR2+
mesodermal cells could grow and differentiate on type IV
collagen-coated dishes under a chemically defined serum-free
condition. In the serum-free culture, sorted VEGFR2+ cells
could differentiate in a VEGF dose-dependent manner into ECs defined by
the expression of vascular endothelial-cadherin (VE-cadherin),26 platelet-endothelial cell adhesion
molecule 1 (PECAM-1)/CD31,27 CD34,28 and
tyrosine kinase with immunoglobulin and endothelial growth factor (EGF)
homology domains 2/tunica interna endothelial cell kinase
(TIE2/TEK).29 VEGF requirement in culture of
VEGFR2+ mesodermal cells was greater in the maintenance
than induction of ECs, which correlated with the delayed expression of
VEGFR1. The chemically defined serum-free culture system described here provides a new tool for assessing different factors for the
proliferation and differentiation of VEGFR2+ mesodermal cells.
Monoclonal antibodies
Cell culture
To induce the differentiation of VEGFR2+ mesodermal cells
under a chemically defined condition, VEGFR2+ cells were
sorted and recultured on type IV collagen-coated dishes in RPMI
1640/Dulbecco modified Eagle medium (DMEM)/F12-based defined medium
SFO3 (Sanko Junyaku, Chiba, Japan)34 containing 0.1% bovine serum albumin (BSA; Sigma) and 5 × 10 Flow cytometry and cell sorting After 4 days for ES cell differentiation, cultured cells were harvested by incubating with cell dissociation buffer (Gibco). The harvested cells were incubated in mouse serum for 20 minutes on ice to block the nonspecific antibody binding, incubated with allophycocyanin (APC)-conjugated AVAS12 and FITC-conjugated ECCD2 for 15 minutes on ice. Cells were washed with Hanks balanced salt solution (Gibco) containing 1% BSA (Seikagaku Kogyo, Tokyo, Japan) and 0.05% sodium azide (Wako Chemical, Osaka, Japan). Living VEGFR2+ E-cadherin-negative cells excluding propidium iodide (Sigma) were sorted by FACS Vantage (Becton Dickinson).After 4 days for ES cell differentiation or 2 to 4 days for VEGFR2+ cell differentiation, cultured cells were harvested and stained with a mixture of MoAbs containing APC-conjugated AVAS12, FITC-conjugated Mec13.3, FITC-conjugated RAM34, biotinylated VECD1, biotinylated TEK4, or biotinylated 5B12 and developed by streptavidin-conjugated R-phycoerythrin (Gibco). Cells were analyzed by FACS Vantage while being gated to exclude small debris, dying cells, and other sources of background interference. Double immunostaining for smooth muscle cell and endothelial cell markers The cultured VEGFR2+ cells were fixed in situ by 5% dimethyl sulfoxide (Nacalai Tesque, Kyoto, Japan) in methanol for 3 minutes at 4°C. After washing with phosphate-buffered saline (PBS), 2% skim milk in PBS was incubated as a blocking solution for 1 hour at room temperature. The fixed dishes were incubated with 1A4 and VECD1 MoAbs overnight at 4°C, followed by incubating with horseradish peroxidase (HRP)-conjugated antimouse immunoglobulin G (IgG; Zymed Laboratories, San Francisco, CA) and alkaline phosphatase (ALP)-conjugated antirat IgG (Jackson Immunoresearch Laboratories, West Grove, PA) for 1 hour at room temperature. After each step, the cultured cells were washed 3 times with PBS containing 0.05% Tween 20 (Wako Chemical). Cells were visualized by using first 3,3'-diaminobenzidine (DAB) substrate (Dojindo, Kumamoto, Japan) for HRP staining and next nitroblue tetrazolium/5-bromo-4-chloro-3-inodolyl phosphate (NBT/BCIP) substrate (Boehringer Mannheim, Germany) for ALP staining. Endogenous HRP or ALP activity was blocked by hydroperoxide (Wako Chemical) or 2 mM levamisole (Sigma), respectively.Quantification of VEGFR1 mRNA Cells were directly sorted into tubes containing Trizol (Sigma) and mRNA was extracted according to the manufacturer's protocol. First-strand cDNA was synthesized from 2 µg total RNA using Superscript First-Strand Synthesis System for reverse transcriptase-polymerase chain reaction (RT-PCR; Gibco BRL). Quantification of VEGFR1 and VEGFR2 mRNA was performed by the LightCycler (Roche Diagnostics, Basel, Switzerland) using FITC- and LcRed-labeled hybriprobes. We measured mRNA of VEGFR1, VEGFR2, and GAPDH. Sense/antisense primer sets used for VEGFR1, VEGFR2, and GAPDH were 5'-ATTACATCCCCCTCAATGCC-3'/5'-GCTCAGATTCATCGTCCTGC-3', 5'-AGGCTCCAACCAGACCAGT-3'/5'-CTAAGCAGCACCTCTCTCGT-3', and 5'-TGAACGGGAAGCTCACTGG-3'/5'-TCCACCACCCTGTTGCTGTA-3', respectively. Hybriprobes used for VEGFR1, VEGFR2, and GAPDH were 5'-CCCCTTGCTGAAGCGGTTCAC-3'-FITC/LcRed640-5'-TGGACTGAGACCAAGCCCAAGG-3'-P, 5'-TCCAGCGACGAGGCAGGACTTTTA-3'-FITC/LcRed640-5'-AGATGGTGGATGCTGCAGTTCACG-3'-P, and 5'-GCATCTTGGGCTACACTGAGGACC-3'-FITC/LcRed640-5'-GGTTGTCTCCTGCGACTTCAACAG-3'-P, respectively. A standard curve was prepared with 10 to 105 copies of purified plasmids containing VEGFR1, VEGFR2, and GAPDH. The amount of mRNA was normalized against the GAPDH mRNA content.
Serum-free culture of ES cell-derived VEGFR2+ mesodermal cells VEGFR2+ E-cadherin-negative mesodermal cells were generated from ES cells on type IV collagen-coated dishes by incubating for 4 days in the culture supplemented with FCS and were purified by fluorescence-activated cell sorting (Figure 1A). At this stage, VEGFR2+ cells did not express EC or HC markers such as PECAM-1, TIE2, VE-cadherin, CD34, or CD45 (Figure 1B and data not shown). Our previous studies demonstrated that the differentiation of ES cells through VEGFR2+ mesodermal cells into EC and HC lineages occurred in the medium supplemented with FCS without addition of exogenous VEGF.13,25 On the other hand, gene knock-out studies demonstrated that VEGF was essential for EC differentiation.4,5 It is thus likely that animal sera contain VEGF or its equivalents that supported the growth of VEGFR2+ cells in the culture described previously.10 This highlighted the importance of using defined culture conditions for assessing activities of soluble factors, particularly such a molecule as VEGF that exerts its effect in a dose-dependent manner.
To start searching for the defined medium for EC differentiation,
we selected first RPMI 1640/DMEM/F12-based defined medium SFO3, which
we have developed for culturing hematopoietic stem cells.34 To test whether or not SFO3 could support
differentiation of VEGFR2+ cells into ECs, sorted
VEGFR2+ cells were cultured on type IV collagen-coated
dishes in SFO3 medium. As observed under phase contrast microscopy,
SFO3 supported growth and differentiation of these cells to some extent
in the absence of VEGF (Figure 2A-B).
However, the expressions of VEGFR2 as well as of other EC markers were
barely observed in the cultured cells for 3 days (Figure
3A). These results are consistent with previous in vivo studies showing absolute requirement of VEGF for the
differentiation of ECs from the mesoderm.11,12
Effect of VEGF on the differentiation of VEGFR2+ cells under serum-free conditions We next investigated whether or not the addition of VEGF to the culture of VEGFR2+ mesodermal cells could support their differentiation to ECs. Sorted VEGFR2+ cells were cultured on type IV collagen-coated dishes in SFO3 medium supplemented with 50 ng/mL VEGF. As observed under phase contrast microscopy, these cells could grow and form a population mostly with spindle-shaped cells (Figure 2C-D). In contrast to culture without VEGF, nearly 40% of cells after 3 days of culture with VEGF were positive for VEGFR2 and coexpressed VE-cadherin, PECAM-1, CD34, and TIE2 (Figure 3B), although the expression of EC markers in VEGFR2+ cell population was variable among markers. As we demonstrated previously,16 mural cells positive for -smooth muscle actin were other lineage
cells derived from VEGFR2+ mesodermal cells. Almost all the
cells negative for EC markers after 3 days of serum-free culture in the
absence of VEGF were actually positive for -smooth muscle actin
(data not shown). Double staining with anti-VE-cadherin and
anti--smooth muscle actin MoAbs showed that ECs with spindle shape
and mural cells with dendritic shape were the major populations
generated after 2 days of this serum-free culture in the
presence of VEGF (Figure 2E-F). These results indicates that VEGF
alone is sufficient to induce differentiation of VEGFR2+
mesoderm cells into ECs, although involvement of other cellular factors
generated from the cultured cells themselves should be taken into account.
Effects of VEGF concentration on EC differentiation We next investigated whether or not VEGF-induced EC differentiation from VEGFR2+ mesodermal cells occurs in a VEGF dose-dependent manner. VEGFR2+ mesodermal cells were cultured in the presence of serially diluted VEGF, and the generation of VE-cadherin-positive CD34+ ECs was measured after 4 days of culture. Cell recoveries at day 4 of culture were comparable over those VEGF concentrations (1.3, 1.6, 1.4, 1.0, 1.1, 1.2, or 1.1 × 106 at 0, 4, 8, 16, 32, 64, or 128 ng/mL VEGF, respectively). However, the proportion of VE-cadherin-positive CD34+ cells increased in a dose-dependent manner over the range of VEGF concentrations tested here (Figure 4). Such a stoichiometric VEGF dependency in EC generation may be relevant to the previous observation that a 50% reduction of VEGF in the VEGF+/ embryos
resulted in impaired vascular development.
Interestingly, when the assay was performed after 2 days of
culture, the stoichiometric VEGF dependency was less evident and the
comparable number of VE-cadherin-positive CD34+ cells was
generated both at 30 and 60 ng/mL VEGF (Figure
5; 2-day culture; cell recoveries at 30 or 60 ng/mL VEGF was 8.4 or 9.0 × 105/culture,
respectively). On the other hand, VE-cadherin-positive C34+ cells could not be maintained for the next 2 days of
culture with lower concentration of VEGF (Figure 5, 4 day culture; cell recoveries at 30 or 60 ng/mL VEGF was 8.0 or
7.6 × 106/culture, respectively). These results suggest
that stoichiometric VEGF dependency is more evident in the maintenance
rather than induction of ECs.
Role for VEGFR1 in VEGF-dependent EC differentiation A line of evidence indicated that a major function of VEGFR1 during embryogenesis was to regulate VEGFR2 signal negatively by sequestering VEGF rather than to transduce the VEGFR1 signal itself. Because the in vivo expression of VEGFR1 was suggested to be later than that of VEGFR2 during EC differentiation,19 it is plausible that the failure of EC maintenance in the late phase of culture was due to the antagonistic activity of VEGFR1 that is newly synthesized in developing ECs. To quantify the change of mRNA level of VEGFR1 compared with that of VEGFR2 during EC maturation, VEGFR2+ mesodermal cells were cultured in the presence of 30 ng/mL VEGF and VEGFR2+ cells were purified from the culture after 1 and 2 days. The amount of VEGFR2 mRNA was comparable during EC maturation (17.19 ± 0.44, 17.55 ± 0.55, and 17.21 ± 0.24 copies/cell, for the initiation, day 1, and day 2 of culture, respectively). On the other hand, the amount of VEGFR1 mRNA expressed in the VEGFR2+ cells rapidly increased during first 2 days of culture (0.902 ± 0.02, 6.03 ± 0.09, and 11.9 ± 1.4 copies/cell, for the initiation, day 1 and day 2 of culture, respectively). This result is consistent with a previous report that VEGF up-regulates VEGFR-1 expression at the transcriptional level in ECs.36 To confirm that this increase in mRNA of VEGFR1 is represented by the surface expression at the protein level, we analyzed VEGFR1 expression in the VEGFR2+ population before and after the culture in the serum-free medium containing 30 ng/mL VEGF. As shown in Figure 6, VEGFR1 expression increased during the culture (4.5-fold in this particular experiment). This increase was observed only in the VEGFR2+ population. The quantification of mRNA and protein levels showed that expression of VEGFR1 was later than that of VEGFR2 and the amount of VEGFR1 became close to that of VEGFR2 during in vitro EC maturation.
To investigate whether or not delayed expression of VEGFR1 was
responsible for the stoichiometric relationship between dose of VEGF
and maintenance of VE-cadherin-positive CD34+ cells, we
took advantage of VEGF-E that is a virus-derived ligand for VEGFR2 but
not for VEGFR1. VEGFR2+ cells were cultured in the presence
or absence of VEGF or VEGF-E (Figure 7).
Twenty or 40 ng/mL VEGF or VEGF-E induced comparable levels of
VE-cadherin-positive CD34+ cells after 2 days of culture.
When the assay was performed after 4 days of culture, VEGF at these
doses failed to maintain VE-cadherin-positive CD34+ cells
in vitro, whereas no marked reduction of this population was observed
in the culture with VEGF-E. On the contrary, its proportion increased
slightly during another 48 hours from day 2 of culture with VEGF-E.
These results suggested that greater requirement of VEGF at late phase
of EC differentiation was due to the delayed expression of VEGFR1 in
VEGFR2+ cells.
The main purpose of this study is to establish an experimental system that allows assessment of the effects of soluble factors such as VEGF on the ECs and their progenitors. Fortunately, the serum-free culture medium SFO3, which we have developed for culturing hematopoietic stem cells, could also support the proliferation and differentiation of ECs from VEGFR2+ mesoderm cells. VEGF has been implicated as the major growth factor for developing ECs.
The number of VE-cadherin-positive CD34+ cells harvested
after 3 to 4 days of incubation correlated well with the dose of VEGF
under the defined culture condition. Because embryonic lethality of
VEGF+/ What is the molecular basis underlying the delayed appearance of the stoichiometric pattern of VEGF dose responsiveness? One possibility is that the property of the signal transduction pathway in the downstream of VEGFR2 changes along with EC differentiation. This possibility, however, cannot explain our observation that the in vitro response of VEGFR2+ cells to VEGF-E, another ligand for VEGFR2, differed from that of VEGF in terms of dose dependency. It is of note that the level of VEGFR1 expression increases rapidly during first 2 days of culture in VEGFR2+ cells. Because VEGFR1 has been shown to play a role in antagonizing VEGFR2 during early embryogenesis, another possibility is that the increase of VEGFR1 expression level during EC differentiation is the reason for the shift of VEGF dose responsiveness. This possibility is strongly supported by the observation that response of VEGFR2+ mesodermal cells to VEGF-E that is not antagonized by VEGFR1 was not dose sensitive even at late phase of culture. It was reported that the expression of VEGFR1 was first turned on at the early primitive streak stage and that the expression level reached a maximum at about midsomite stage when the extraembryonic vascular plexus has already developed.20 This kinetics of VEGFR1 expression is consistent with our results on ES cells cultured in vitro. A previous in vitro experiment also demonstrated that VEGF up-regulates VEGFR1 expression in ECs.36 Taken together, it is most likely that VEGF acts on VEGFR2+ mesodermal cells to induce the differentiation into ECs as well as to up-regulate the expression of VEGFR1 that consequently sequesters VEGF from VEGFR2 signal. To our knowledge, the present result would be the first case demonstrating the correlation between differential level of VEGFR1 expression and differential dose of VEGF requirement. It should be emphasized that this in vitro finding was enabled only by the establishment of the defined culture condition that supported EC differentiation. Our experiment using a serum-free culture system clearly demonstrated that VEGF alone is sufficient for supporting the generation of ECs from VEGFR2+ mesoderm cells, whereas factors produced by cultured cells themselves may be also involved. We observed that ECs and mural cells were the major cell types in this culture. Because smooth muscle cells are known to produce VEGF in vitro,37 we have to take the effects of VEGF family ligands produced in culture on VEGFR2+ cells into account. In the absence of VEGF, VEGFR2+ cells gave rise mostly to mural cells (data not shown). If the effects of VEGFs produced by these cells were significant, the growth factors could induce the differentiation of VEGFR2+ cells into ECs in a paracrine fashion. However, it was not the case. The stoichiometric VEGF dependency in EC generation shown here also suggested that VEGF added exogenously was a more significant growth factor than VEGFs produced endogenously in this culture. We are well aware that the scheme drawn in the in vitro system is far simpler than what happens in the actual embryo. For example, VEGF-C38 binds to VEGFR2 and Flt4/VEGFR339 but not to VEGFR1. It is likely that in the local region where VEGF-C is expressed together with VEGF, the VEGFR2 signal may remain less affected by the increase of VEGFR1 expression. It is also the case with VEGF-D40 in the human, whereas it may not be the case with mouse VEGF-D that does not bind to VEGFR2.41 On the other hand, in the situation where only VEGF is available, ECs are highly sensitive to a change of VEGF dose. Reconstitution of those signal systems in the response of ECs in culture should be essential for investigating the role of all these signals in EC behavior, and the defined culture system described here will provide a useful system for this purpose.
We thank Dr M. J. Evans for providing the CCE ES cell line, Dr A. Nagafuchi for ECCD2 MoAb, Dr N. Matsuyoshi for VECD1 MoAb, Dr T. Suda for TEK4 MoAb, and Drs D. Hicklem and P. Bolen for 5B12 MoAb. We also thank Dr M. Osawa for technical assistance and all the members in our laboratory for helpful discussions.
Submitted January 7, 2002; accepted October 21, 2002.
Prepublished online as Blood First Edition Paper, October 24, 2002; DOI 10.1182/blood-2002-01-0003.
Supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology (12219209) and the Organization of Pharmaceutical Safety and Research, and the Ministry of Health, Labor, and Welfare of Japan. M.H. was a recipient of a postdoctoral fellowship from Tsumura and Company.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Shin-Ichi Nishikawa, Department of Molecular Genetics, Graduate School of Medicine, Kyoto University, Shogoin-Kawaharacho 53, Sakyo-Ku, Kyoto, Japan; e-mail: snishika{at}virus.kyoto-u.ac.jp.
1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858[CrossRef][Medline] [Order article via Infotrieve].
2.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N.
Vascular endothelial growth factor is a secreted angiogenic mitogen.
Science.
1989;246:1306-1309
3.
Keck PJ, Hauser SD, Krivi G, et al.
Vascular permeability factor, an endothelial cell mitogen related to PDGF.
Science.
1989;246:1309-1312 4. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439[CrossRef][Medline] [Order article via Infotrieve]. 5. Ferrara N, Carver Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442[CrossRef][Medline] [Order article via Infotrieve]. 6. Haigh JJ, Gerber HP, Ferrara N, Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development. 2000;127:1445-1453[Abstract].
7.
Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR.
A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.
Proc Natl Acad Sci U S A.
1991;88:9026-9030 8. Millauer B, Wizigmann Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835-846[CrossRef][Medline] [Order article via Infotrieve]. 9. Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development. 1993;118:489-498[Abstract]. 10. Kataoka H, Takakura N, Nishikawa S, et al. Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev Growth Differ. 1997;39:729-740[CrossRef][Medline] [Order article via Infotrieve]. 11. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66[CrossRef][Medline] [Order article via Infotrieve]. 12. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981-990[CrossRef][Medline] [Order article via Infotrieve]. 13. Nishikawa SI, Nishikawa S, Hirashima M, Matsuyoshi N, Kodama H. Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development. 1998;125:1747-1757[Abstract].
14.
Eichmann A, Corbel C, Nataf V, Vaigot P, Breant C, Le Douarin NM.
Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2.
Proc Natl Acad Sci U S A.
1997;94:5141-5146 15. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development. 1998;125:725-732[Abstract]. 16. Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000;408:92-96[CrossRef][Medline] [Order article via Infotrieve]. 17. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5:519-524[Medline] [Order article via Infotrieve].
18.
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT.
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science.
1992;255:989-991 19. Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn. 1995;204:228-239[Medline] [Order article via Infotrieve]. 20. Fong GH, Klingensmith J, Wood CR, Rossant J, Breitman ML. Regulation of flt-1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium. Dev Dyn. 1996;207:1-10[CrossRef][Medline] [Order article via Infotrieve]. 21. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70[CrossRef][Medline] [Order article via Infotrieve]. 22. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development. 1999;126:3015-3025[Abstract].
23.
Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M.
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.
Proc Natl Acad Sci U S A.
1998;95:9349-9354
24.
Waltenberger J, Claesson Welsh L, Siegbahn A, Shibuya M, Heldin CH.
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.
J Biol Chem.
1994;269:26988-26995
25.
Hirashima M, Kataoka H, Nishikawa S, Matsuyoshi N, Nishikawa S.
Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis.
Blood.
1999;93:1253-1263
26.
Breier G, Breviario F, Caveda L, et al.
Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system.
Blood.
1996;87:630-641
27.
Newman PJ, Berndt MC, Gorski J, et al.
PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily.
Science.
1990;247:1219-1222
28.
Wood HB, May G, Healy L, Enver T, Morriss Kay GM.
CD34 expression patterns during early mouse development are related to modes of blood vessel formation and reveal additional sites of hematopoiesis.
Blood.
1997;90:2300-2311 29. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene. 1992;7:1471-1480[Medline] [Order article via Infotrieve]. 30. Shirayoshi Y, Nose A, Iwasaki K, Takeichi M. N-linked oligosaccharides are not involved in the function of a cell-cell binding glycoprotein Ecadherin. Cell Struct Funct. 1986;11:245-252[Medline] [Order article via Infotrieve]. 31. Matsuyoshi N, Toda K, Horiguchi Y, et al. In vivo evidence of the critical role of cadherin-5 in murine vascular integrity. Proc Assoc Am Physicians. 1997;109:362-371[Medline] [Order article via Infotrieve]. 32. Takakura N, Huang XL, Naruse T, et al. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity. 1998;9:677-686[CrossRef][Medline] [Order article via Infotrieve]. 33. Robertson E, Bradley A, Kuehn M, Evans M. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature. 1986;323:445-448[CrossRef][Medline] [Order article via Infotrieve]. 34. Nishikawa S, Nakasato M, Takakura N, Ogawa M, Kodama H, Nishikawa S. Stromal cell-dependent bone marrow culture with a nearly protein-free defined medium. Immunol Lett. 1994;40:163-169[CrossRef][Medline] [Order article via Infotrieve].
35.
Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M.
A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain.
J Biol Chem.
1998;273:31273-31282
36.
Barleon B, Siemeister G, Martiny Baron G, Weindel K, Herzog C, Marme D.
Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells.
Cancer Res.
1997;57:5421-5425 37. Ferrara N, Winer J, Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors. 1991;5:141-148[Medline] [Order article via Infotrieve]. 38. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298[Medline] [Order article via Infotrieve].
39.
Aprelikova O, Pajusola K, Partanen J, et al.
FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.
Cancer Res.
1992;52:746-748
40.
Achen MG, Jeltsch M, Kukk E, et al.
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).
Proc Natl Acad Sci U S A.
1998;95:548-553
41.
Baldwin ME, Catimel B, Nice EC, et al.
The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
J Biol Chem.
2001;276:19166-19171
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  Q. Xiao, L. Zeng, Z. Zhang, Y. Hu, and Q. Xu Stem cell-derived Sca-1+ progenitors differentiate into smooth muscle cells, which is mediated by collagen IV-integrin {alpha}1/beta1/{alpha}v and PDGF receptor pathways Am J Physiol Cell Physiol, January 1, 2007; 292(1): C342 - C352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. McGannon, Y. Miyazaki, P. C. Gupta, E. I. Traboulsi, and C. Colmenares Ocular Abnormalities in Mice Lacking the Ski Proto-oncogene. Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4231 - 4237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Xiao, L. Zeng, Z. Zhang, A. Margariti, Z. A Ali, K. M. Channon, Q. Xu, and Y. Hu Sca-1+ Progenitors Derived From Embryonic Stem Cells Differentiate Into Endothelial Cells Capable of Vascular Repair After Arterial Injury Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2244 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, I. Amende, T. G. Hampton, Y. Yang, Q. Ke, J.-Y. Min, Y.-F. Xiao, and J. P. Morgan Vascular endothelial growth factor promotes cardiomyocyte differentiation of embryonic stem cells Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1653 - H1658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kono, H. Kubo, C. Shimazu, Y. Ueda, M. Takahashi, K. Yanagi, N. Fujita, T. Tsuruo, H. Wada, and J. K. Yamashita Differentiation of Lymphatic Endothelial Cells From Embryonic Stem Cells on OP9 Stromal Cells Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2070 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Majka, K. Fox, B. McGuire, J. Crossno Jr., P. McGuire, and A. Izzo Pleiotropic role of VEGF-A in regulating fetal pulmonary mesenchymal cell turnover Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1183 - L1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Kano, Y. Morishita, C. Iwata, S. Iwasaka, T. Watabe, Y. Ouchi, K. Miyazono, and K. Miyazawa VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFR{beta} signaling J. Cell Sci., August 15, 2005; 118(16): 3759 - 3768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, T. Sokabe, T. Watabe, K. Miyazono, J. K. Yamashita, S. Obi, N. Ohura, A. Matsushita, A. Kamiya, and J. Ando Fluid shear stress induces differentiation of Flk-1-positive embryonic stem cells into vascular endothelial cells in vitro Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1915 - H1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. M. Martinez-Estrada, Y. Munoz-Santos, J. Julve, M. Reina, and S. Vilaro Human adipose tissue as a source of Flk-1+ cells: new method of differentiation and expansion Cardiovasc Res, February 1, 2005; 65(2): 328 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. De Falco, D. Porcelli, A. R. Torella, S. Straino, M. G. Iachininoto, A. Orlandi, S. Truffa, P. Biglioli, M. Napolitano, M. C. Capogrossi, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells Blood, December 1, 2004; 104(12): 3472 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zippo, A. De Robertis, M. Bardelli, F. Galvagni, and S. Oliviero Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro Blood, June 15, 2004; 103(12): 4536 - 4544. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
